TY - JOUR T1 - Serial population based serosurvey of antibodies to SARS-CoV-2 in a low and high transmission area of Karachi, Pakistan JF - medRxiv DO - 10.1101/2020.07.28.20163451 SP - 2020.07.28.20163451 AU - Imran Nisar AU - Nadia Ansari AU - Mashal Amin AU - Farah Khalid AU - Aneeta Hotwani AU - Najeeb Rehman AU - Arjumand Rizvi AU - Arslan Memon AU - Zahoor Ahmed AU - Ashfaque Ahmed AU - Junaid Iqbal AU - Ali Faisal Saleem AU - Uzma Bashir AU - Daniel B Larremore AU - Bailey Fosdick AU - Fyezah Jehan Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/29/2020.07.28.20163451.abstract N2 - Background Pakistan is among the first low- and middle-income countries affected by COVID-19 pandemic. Monitoring progress through serial sero-surveys, particularly at household level, in densely populated urban communities can provide insights in areas where testing is non-uniform.Methods Two serial cross-sectional household surveys were performed in April (phase 1) and June (phase 2) 2020 each in a low- (District Malir) and high-transmission (District East) area of Karachi, Pakistan. Household were selected using simple random sampling (Malir) and systematic random sampling (East). Individual participation rate from consented households was 82.3% (1000/1215 eligible) in phase 1 and 76.5% (1004/1312 eligible) in phase 2. All household members or their legal guardians answered questions related to symptoms of Covid-19 and provided blood for testing with commercial Elecsys® Anti-SARS-CoV-2 immunoassay targeting combined IgG andIgM. Seroprevalence estimates were computed for each area and time point independently. Given correlation among household seropositivity values, a Bayesian regression model accounting for household membership, age and gender was used to estimate seroprevalence. These estimates by age and gender were then post-stratified to adjust for the demographic makeup of the respective district. The household conditional risk of infection was estimated for each district and its confidence interval were obtained using a non-parametric bootstrap of households.Findings Post-stratified seroprevalence was estimated to be 0.2% (95% CI 0-0.7) in low-and 0.4% (95% CI 0-1.3) in high-transmission areas in phase 1 and 8.7% (95% CI 5.1-13.1) in low- and 15.1% (95% CI 9.4-21.7) in high-transmission areas in phase 2, with no consistent patterns between prevalence rates for males and females. Conditional risk of infection estimates (possible only for phase 2) were 0.31 (95% CI 0.16-0.47) in low- and 0.41(95% CI 0.28-0.52) in high-transmission areas. Of the 166 participants who tested positive, only 9(5.4%) gave a history of any symptoms.Interpretation A large increase in seroprevalence to SARS-CoV-2 infection is seen, even in areas where transmission is reported to be low. Mostly the population is still seronegative. A large majority of seropositives do not report any symptoms. The probability that an individual in a household is infected, given that another household member is infected is high in both the areas. These results emphasise the need to enhance surveillance activities of COVID-19 especially in low-transmission sites and provide insights to risks of household transmission in tightly knit neighbourhoods in urban LMIC settings.Evidence before this study Pakistan is the fifth most populous country in the world. The pandemic reached here in late February 2020 and so far more than 269000 confirmed cases have been registered with over 5500 deaths. Karachi, the largest city in Pakistan has also seen most number of cases and deaths However, true extent of transmission in the community is not known as testing rates have been low resulting in under reporting of cases and omission of mildly symptomatic and asymptomatic cases Population based serosurveys can help understand true magnitude of the spread and its variation with sociodemographic and other factors We searched PubMed and its specific hub LitCovid, medRxiv and bioRxiv preprint servers up to July 25, 2020, for epidemiological studies using the terms “seroprevalence” or “seroepidemiology” and “SARS-CoV-2” for articles in English language. Although there has been a recent surge in the number of serosurveys that have been done globally, many of them fail to meet the appropriate epidemiological and laboratory requirements of internal and external validity. No survey from Pakistan was identified.Added value of this study This is the first population-based seroprevalence study on estimates of antibodies against SARS-CoV-2 from Pakistan. We recruited more than 2000 participants across all age groups from one low transmission and one high transmission area in Karachi in two phases. Our findings show a huge jump in seroprevalence in both low and high transmission areas. Our findings suggest that in our population around 95% of individuals who have developed antibodies against SARS-CoV-2 were asymptomatic. Additionally, our results indicate that children and adolescents have similar seroprevalence as adults and seroprevalence does not vary by sex. We used a FDA approved lab assay for measuring antibodies.Implications of all the available evidence There was a huge increase seen in seroprevalence observed in both low and high transmission areas over a short period of time. Our results suggest that almost 95% of people with SARS-CoV-2 infection remained asymptomatic in our population, which has important public health implications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Infectious Disease Research Lab at The Aga Khan UniversityAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from Aga Khan University's Ethical review committeeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available on request ER -